董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Justin Roberts | 男 | Director | 40 | 未披露 | 未持股 | 2023-05-17 |
| Cooper C. Collins | 男 | Director | 44 | 12.57万美元 | 未持股 | 2023-05-17 |
| Gail K. Naughton | 女 | Director | 67 | 10.62万美元 | 未持股 | 2023-05-17 |
| Tommy G. Thompson | 男 | Executive Chairman of the Board | 81 | 38.00万美元 | 未持股 | 2023-05-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marlan D. Walker | 男 | Chief Executive Officer | 49 | 141.78万美元 | 未持股 | 2023-05-17 |
董事简历
中英对照 | 中文 | 英文- Justin Roberts
-
贾斯汀·罗伯茨是Rubric Capital Management LP的合伙人，自2016年公司成立以来一直担任该职位。他目前担任Mereo BioPharma [纳斯达克股票代码：MREO ]的非执行董事。在加入Rubric之前，他在Point72资产管理公司工作了七年。罗伯茨先生还曾在摩尔资本管理公司ZS联合公司任职，他的职业生涯始于雷曼兄弟的并购业务投资银行家。
Justin Roberts,is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. He currently serves as a Non-Executive Director of Mereo BioPharma [NASDAQ: MREO]. Before Rubric, he spent seven years at Point72 Asset Management. Mr. Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice. - 贾斯汀·罗伯茨是Rubric Capital Management LP的合伙人，自2016年公司成立以来一直担任该职位。他目前担任Mereo BioPharma [纳斯达克股票代码：MREO ]的非执行董事。在加入Rubric之前，他在Point72资产管理公司工作了七年。罗伯茨先生还曾在摩尔资本管理公司ZS联合公司任职，他的职业生涯始于雷曼兄弟的并购业务投资银行家。
- Justin Roberts,is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. He currently serves as a Non-Executive Director of Mereo BioPharma [NASDAQ: MREO]. Before Rubric, he spent seven years at Point72 Asset Management. Mr. Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice.
- Cooper C. Collins
-
Cooper C. Collins自2012年2月起担任本公司董事。Collins先生自2015年6月起担任富通生物制药有限责任公司首席执行官。Collins先生于2013年5月至2014年4月担任Pernix Therapeutics Holdings，Inc.【NASDAQ：PTX】或Pernix的首席战略官，2010年3月至2013年5月担任总裁兼首席执行官，2010年3月至2014年2月担任董事。Collins先生于2002年加入Pernix Therapeutics，Inc.，Pernix的前身，2007年1月被任命为董事，2007年12月被任命为总裁，2008年6月被任命为首席执行官，在这三个职位上任职至2010年3月。2005年12月至2007年12月，Collins先生担任Pernix Therapeutics，Inc.业务和产品开发副总裁，并于2003年12月至2005年12月担任其区域经理。Collins先生受雇于美国国家足球联盟（National Football League League）旗下媒体关系部的新奥尔良圣徒队（the New Orleans Saints）工作了三年。
Cooper C. Collins,has served as a director of Therapeuticsmd, Inc. Company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. - Cooper C. Collins自2012年2月起担任本公司董事。Collins先生自2015年6月起担任富通生物制药有限责任公司首席执行官。Collins先生于2013年5月至2014年4月担任Pernix Therapeutics Holdings，Inc.【NASDAQ：PTX】或Pernix的首席战略官，2010年3月至2013年5月担任总裁兼首席执行官，2010年3月至2014年2月担任董事。Collins先生于2002年加入Pernix Therapeutics，Inc.，Pernix的前身，2007年1月被任命为董事，2007年12月被任命为总裁，2008年6月被任命为首席执行官，在这三个职位上任职至2010年3月。2005年12月至2007年12月，Collins先生担任Pernix Therapeutics，Inc.业务和产品开发副总裁，并于2003年12月至2005年12月担任其区域经理。Collins先生受雇于美国国家足球联盟（National Football League League）旗下媒体关系部的新奥尔良圣徒队（the New Orleans Saints）工作了三年。
- Cooper C. Collins,has served as a director of Therapeuticsmd, Inc. Company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department.
- Gail K. Naughton
-
Gail K. Naughton担任Histogen再生医药有限公司的董事长和首席执行官。Dr. Naughton自2007年6月担任Histogen有限公司的董事长和首席执行官，从2002年3月至2002年10月担任Advanced Tissue Sciences有限公司（ATS）（人类基础组织工程）副董事长，自2000年8月至2002年3月担任总裁。 ，自1995年至2000年担任总裁和首席运营官，在1991年是合作创始人和主管。 Dr. Naughton从2002年8月至2011年6月还担任圣地亚哥州立大学的商业学院的行政院长。Dr. Naughton担任Celera 公司和SYS 科技有限公司的前主管。Dr. Naughton担任管理委员会、法律法规委员会、科学技术委员会成员。Dr. Naughton因其广泛的生命科学产业知识与经验，包括Histogen有限公司的董事长和首席执行官，被提名特别组主管 。Dr. Naughton 是第一位获得由知识产权所有协会颁发的国家年度发明奖的女性。她指导超过美国及95个国外的拓展研究、授权大量科学出版物。 Dr. Naughton 还有着著名的学术生涯，包括担任经济管理学院的院长，圣地亚哥大学和几个学术组织的董事会成员，非盈利组织和基金会成员。Dr. Naughton获得纽约Brooklyn Francis学院的理学士学位，纽约大学医学中心组织学理学硕士和血液学博士学位。她还在洛杉矶加利福尼亚大学Anderson学院获得行政管理工商管理硕士学位 。
Gail K. Naughton,has served as a director of Therapeuticsmd, Inc. Company since March 2020. Dr. Naughton has been the CEO of Regenemed Associates since June of 2021 and the Executive Chair of BiOHIP Inc. since October of 2021. Dr. Naughton served as the Chairman and Chief Executive Officer of Histogen Inc., or Histogen, from June 2007 until April 2017. Prior to Histogen, Dr. Naughton served as an Officer of Advanced Tissue Sciences, Inc., a human-based tissue engineering company, from 1991 to October 2002. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She has spent over 35 years extensively researching the tissue engineering process, holds over 135 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica's TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of regenerative medicine. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton also serves as a member of the board of directors for CEL-SCI Corporation [NYSE American: CVM] and previously served as a member of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until January 2018. - Gail K. Naughton担任Histogen再生医药有限公司的董事长和首席执行官。Dr. Naughton自2007年6月担任Histogen有限公司的董事长和首席执行官，从2002年3月至2002年10月担任Advanced Tissue Sciences有限公司（ATS）（人类基础组织工程）副董事长，自2000年8月至2002年3月担任总裁。 ，自1995年至2000年担任总裁和首席运营官，在1991年是合作创始人和主管。 Dr. Naughton从2002年8月至2011年6月还担任圣地亚哥州立大学的商业学院的行政院长。Dr. Naughton担任Celera 公司和SYS 科技有限公司的前主管。Dr. Naughton担任管理委员会、法律法规委员会、科学技术委员会成员。Dr. Naughton因其广泛的生命科学产业知识与经验，包括Histogen有限公司的董事长和首席执行官，被提名特别组主管 。Dr. Naughton 是第一位获得由知识产权所有协会颁发的国家年度发明奖的女性。她指导超过美国及95个国外的拓展研究、授权大量科学出版物。 Dr. Naughton 还有着著名的学术生涯，包括担任经济管理学院的院长，圣地亚哥大学和几个学术组织的董事会成员，非盈利组织和基金会成员。Dr. Naughton获得纽约Brooklyn Francis学院的理学士学位，纽约大学医学中心组织学理学硕士和血液学博士学位。她还在洛杉矶加利福尼亚大学Anderson学院获得行政管理工商管理硕士学位 。
- Gail K. Naughton,has served as a director of Therapeuticsmd, Inc. Company since March 2020. Dr. Naughton has been the CEO of Regenemed Associates since June of 2021 and the Executive Chair of BiOHIP Inc. since October of 2021. Dr. Naughton served as the Chairman and Chief Executive Officer of Histogen Inc., or Histogen, from June 2007 until April 2017. Prior to Histogen, Dr. Naughton served as an Officer of Advanced Tissue Sciences, Inc., a human-based tissue engineering company, from 1991 to October 2002. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She has spent over 35 years extensively researching the tissue engineering process, holds over 135 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica's TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of regenerative medicine. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton also serves as a member of the board of directors for CEL-SCI Corporation [NYSE American: CVM] and previously served as a member of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until January 2018.
- Tommy G. Thompson
-
Tommy G. Thompson，他曾担任Therapeuticsmd, Inc.的董事会主席和董事。从2012年5月到2022年9月6日被任命为董事会执行主席。从2020年7月到2022年3月，Thompson秘书担任University of Wisconsin系统的临时校长。他还担任Thompson Holdings（一家咨询公司）的首席执行官。从1987年1月到2001年2月担任Wisconsin州长期间，Thompson部长最为人所知的可能是他为振兴Wisconsin经济所做的努力，他在福利改革方面的全国领导地位，以及他为扩大社会各阶层的医疗保健覆盖面所做的工作。从2001年2月到2005年1月，Thompson部长担任美国卫生与人类服务部（HHS）的前部长，担任全国所有美国人健康和福利的主要倡导者。从2005年3月到2012年1月，Thompson秘书是Akin Gump Strauss Hauer & Feld LLP律师事务所（或Akin Gump）的合伙人，当时他辞职竞选美国参议院。从2005年3月到2009年5月，Thompson秘书担任Deloitte Center for Health Solutions（一家医疗保健咨询公司）的独立董事长。在Deloitte健康解决方案中心和Akin Gump，Thompson部长继续他在卫生与公众服务部的工作，致力于制定解决美国家庭、企业、社区、州和整个国家面临的医疗保健挑战的解决方案。从2005年2月到2011年1月，Thompson还担任Logistics Health, Inc.（医疗准备和国土安全解决方案的供应商）的总裁。Thompson自2013年7月起担任两党政策中心（一个专注于两党倡导和政策制定的非营利组织）的高级研究员。Thompson还担任United Therapeutics Corporation（NASDAQ：UTHR）和Physicians Realty Trust（纽约证券交易所股票代码：DOC）的董事会成员。Thompson秘书还曾担任Tyme Technologies, Inc.（NASDAQ：TYMI）（2017年8月至2020年2月），C. R. Bard, Inc.（纽约证券交易所股票代码：BCR）（2005年8月至2018年1月）和Centene Corporation（纽约证券交易所股票代码：CNC）（2005年4月至2022年1月）的董事会成员，并曾担任其他上市公司的董事会成员。
Tommy G. Thompson,served as the Chairman of the Board of Directors and a director of Therapeuticsmd, Inc. Company from May 2012 until he was appointed as Executive Chairman of the Board of Directors on September 6, 2022. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S. Department of Health & Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation's leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer & Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company, from March 2005 to May 2009. At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a non-profit organization focused on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for United Therapeutics Corporation [NASDAQ: UTHR] and Physicians Realty Trust [NYSE: DOC]. Secretary Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February 2020, C. R. Bard, Inc. [NYSE: BCR] from August 2005 to January 2018 and Centene Corporation [NYSE: CNC] from April 2005 to January 2022, and has historically served on the boards of directors of other public companies. - Tommy G. Thompson，他曾担任Therapeuticsmd, Inc.的董事会主席和董事。从2012年5月到2022年9月6日被任命为董事会执行主席。从2020年7月到2022年3月，Thompson秘书担任University of Wisconsin系统的临时校长。他还担任Thompson Holdings（一家咨询公司）的首席执行官。从1987年1月到2001年2月担任Wisconsin州长期间，Thompson部长最为人所知的可能是他为振兴Wisconsin经济所做的努力，他在福利改革方面的全国领导地位，以及他为扩大社会各阶层的医疗保健覆盖面所做的工作。从2001年2月到2005年1月，Thompson部长担任美国卫生与人类服务部（HHS）的前部长，担任全国所有美国人健康和福利的主要倡导者。从2005年3月到2012年1月，Thompson秘书是Akin Gump Strauss Hauer & Feld LLP律师事务所（或Akin Gump）的合伙人，当时他辞职竞选美国参议院。从2005年3月到2009年5月，Thompson秘书担任Deloitte Center for Health Solutions（一家医疗保健咨询公司）的独立董事长。在Deloitte健康解决方案中心和Akin Gump，Thompson部长继续他在卫生与公众服务部的工作，致力于制定解决美国家庭、企业、社区、州和整个国家面临的医疗保健挑战的解决方案。从2005年2月到2011年1月，Thompson还担任Logistics Health, Inc.（医疗准备和国土安全解决方案的供应商）的总裁。Thompson自2013年7月起担任两党政策中心（一个专注于两党倡导和政策制定的非营利组织）的高级研究员。Thompson还担任United Therapeutics Corporation（NASDAQ：UTHR）和Physicians Realty Trust（纽约证券交易所股票代码：DOC）的董事会成员。Thompson秘书还曾担任Tyme Technologies, Inc.（NASDAQ：TYMI）（2017年8月至2020年2月），C. R. Bard, Inc.（纽约证券交易所股票代码：BCR）（2005年8月至2018年1月）和Centene Corporation（纽约证券交易所股票代码：CNC）（2005年4月至2022年1月）的董事会成员，并曾担任其他上市公司的董事会成员。
- Tommy G. Thompson,served as the Chairman of the Board of Directors and a director of Therapeuticsmd, Inc. Company from May 2012 until he was appointed as Executive Chairman of the Board of Directors on September 6, 2022. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S. Department of Health & Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation's leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer & Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company, from March 2005 to May 2009. At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a non-profit organization focused on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for United Therapeutics Corporation [NASDAQ: UTHR] and Physicians Realty Trust [NYSE: DOC]. Secretary Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February 2020, C. R. Bard, Inc. [NYSE: BCR] from August 2005 to January 2018 and Centene Corporation [NYSE: CNC] from April 2005 to January 2022, and has historically served on the boards of directors of other public companies.
高管简历
中英对照 | 中文 | 英文- Marlan D. Walker
Marlan D. Walker，自2022年12月起担任Therapeuticsmd, Inc.公司首席执行官。2016年3月起担任Therapeuticsmd, Inc.公司总法律顾问。Walker先生还曾于2018年4月至2019年12月担任首席开发官，并于2013年6月担任Therapeuticsmd, Inc.公司和知识产权法律顾问，直至成为Therapeuticsmd, Inc.总法律顾问。沃克的经验主要集中在生命科学行业各种学科的法律问题和风险管理方面。在TherapeuticsMD任职之前，他的法律业务包括长期投资组合战略和管理、专利准备和起诉、合同谈判和起草、生命周期管理以及Hatch-Waxman事务。法学院毕业后，他于2005年8月在Greenberg Traurig，LLP任职。2009年3月，他转会至Luce Forward Hamilton & Scripps。2011年6月，Walker先生接受了Medicis Pharmaceutical Corp.的内部知识产权顾问职位，该公司于2012年12月被Valeant Pharmaceutical International，Inc.收购。2013年2月，Walker先生接受了Kilpatrick Townsend & Stockton的一个职位，但在2013年6月，他接受了Therapeuticsmd, Inc.公司的一个职位，再次选择搬到公司内部。沃克于2004年毕业于亚利桑那州立大学桑德拉·戴·奥康纳法学院，获得法学博士学位，并于2005年在乔治·华盛顿大学法学院获得知识产权法法学硕士学位。他拥有分子生物学硕士学位和学士学位，均毕业于杨百翰大学。
Marlan D. Walker,has served as Chief Executive Officer of Therapeuticsmd, Inc. Company since December 2022. Previously he served as General Counsel of Therapeuticsmd, Inc. Company from March 2016. Mr. Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as Therapeuticsmd, Inc. Corporate and Intellectual Property Counsel from June 2013 until he became Therapeuticsmd, Inc. General Counsel. Mr. Walker's experience is focused in management of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD included long-term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life-cycle management, and Hatch-Waxman matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009, he moved to Luce Forward Hamilton & Scripps. Mr. Walker accepted an in-house position as Intellectual Property Counsel for Medicis Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013, Mr. Walker accepted a position at Kilpatrick Townsend & Stockton, but chose to move in-house again in June 2013, when he accepted a position at Therapeuticsmd, Inc. Company. Mr. Walker graduated from Arizona State University Sandra Day O'Connor College of Law with his J.D. in 2004, and an LL.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master's Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University.- Marlan D. Walker，自2022年12月起担任Therapeuticsmd, Inc.公司首席执行官。2016年3月起担任Therapeuticsmd, Inc.公司总法律顾问。Walker先生还曾于2018年4月至2019年12月担任首席开发官，并于2013年6月担任Therapeuticsmd, Inc.公司和知识产权法律顾问，直至成为Therapeuticsmd, Inc.总法律顾问。沃克的经验主要集中在生命科学行业各种学科的法律问题和风险管理方面。在TherapeuticsMD任职之前，他的法律业务包括长期投资组合战略和管理、专利准备和起诉、合同谈判和起草、生命周期管理以及Hatch-Waxman事务。法学院毕业后，他于2005年8月在Greenberg Traurig，LLP任职。2009年3月，他转会至Luce Forward Hamilton & Scripps。2011年6月，Walker先生接受了Medicis Pharmaceutical Corp.的内部知识产权顾问职位，该公司于2012年12月被Valeant Pharmaceutical International，Inc.收购。2013年2月，Walker先生接受了Kilpatrick Townsend & Stockton的一个职位，但在2013年6月，他接受了Therapeuticsmd, Inc.公司的一个职位，再次选择搬到公司内部。沃克于2004年毕业于亚利桑那州立大学桑德拉·戴·奥康纳法学院，获得法学博士学位，并于2005年在乔治·华盛顿大学法学院获得知识产权法法学硕士学位。他拥有分子生物学硕士学位和学士学位，均毕业于杨百翰大学。
- Marlan D. Walker,has served as Chief Executive Officer of Therapeuticsmd, Inc. Company since December 2022. Previously he served as General Counsel of Therapeuticsmd, Inc. Company from March 2016. Mr. Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as Therapeuticsmd, Inc. Corporate and Intellectual Property Counsel from June 2013 until he became Therapeuticsmd, Inc. General Counsel. Mr. Walker's experience is focused in management of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD included long-term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life-cycle management, and Hatch-Waxman matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009, he moved to Luce Forward Hamilton & Scripps. Mr. Walker accepted an in-house position as Intellectual Property Counsel for Medicis Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013, Mr. Walker accepted a position at Kilpatrick Townsend & Stockton, but chose to move in-house again in June 2013, when he accepted a position at Therapeuticsmd, Inc. Company. Mr. Walker graduated from Arizona State University Sandra Day O'Connor College of Law with his J.D. in 2004, and an LL.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master's Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University.